Japan market size · Molecule

Alectinib Hydrochloride in Japan

アレクチニブ塩酸塩 · その他の腫瘍用薬

The prescription value of Alectinib Hydrochloride in Japan was an estimated ¥38.0 billion in FY2024 (April 2024–March 2025), 2.0% of other antineoplastic agents. Value changed +4.5% year on year and +4.6% a year on average over the last three years. It is supplied by 1 companies under 1 products (all shipping normally).

¥38.0bnValue FY2024 (est.)

+4.5%Year on year

+4.6%3-year average growth

Trend and related drugs

Hover or tap a year for the values. Related drugs are shown as an index so that growth can be compared.

Trend

Prescription value (est.)YoY upYoY down

Compared with related drugs (FY2021 = 100)

Other antineoplastic agents: molecules and supply status All markets

Need the numbers behind the lines?

Year-by-year values for each related drug, company-level shares, and Excel downloads are available to our clients in Japan. Tell us what you are looking at and we will reply in English.

About the data

Values are estimates: prescription volumes from Japan's NDB Open Data (Ministry of Health, Labour and Welfare; excluding public-expense claims), FY2015–FY2024, multiplied by the NHI reimbursement price of each product at the time of each release (nominal). All strengths and brands of the molecule are combined. Japanese fiscal years run from April to March (FY2024 = April 2024 – March 2025). Until FY2023 the NDB lists only the top products by volume in each therapeutic class; years in which a molecule is not listed are shown as “not listed”. Growth rates compare the same products in consecutive years and are chained; the 3-year rate is not shown when the base year value is below one tenth of the latest year. The comparison with related drugs is an index with FY2021 = 100. Supply: MHLW, as of 2026-09-27.